Cargando…

Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction

Women who are at high risk of breast cancer can be offered chemoprevention. Chemoprevention strategies have expanded over the past decade and include selective receptor modulator inhibitors and aromatase inhibitors. Physicians are expected to provide individualized risk assessments to identify high...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahman, Rakhshanda Layeequr, Pruthi, Sandhya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712728/
https://www.ncbi.nlm.nih.gov/pubmed/24213502
http://dx.doi.org/10.3390/cancers4041146
_version_ 1782277108454653952
author Rahman, Rakhshanda Layeequr
Pruthi, Sandhya
author_facet Rahman, Rakhshanda Layeequr
Pruthi, Sandhya
author_sort Rahman, Rakhshanda Layeequr
collection PubMed
description Women who are at high risk of breast cancer can be offered chemoprevention. Chemoprevention strategies have expanded over the past decade and include selective receptor modulator inhibitors and aromatase inhibitors. Physicians are expected to provide individualized risk assessments to identify high risk women who may be eligible for chemoprevention. It is prudent that physicians utilize a shared decision approach when counseling high risk women about their preventive options. Barriers and misperceptions however exist with patient and physician acceptance of chemoprevention and continue to impede uptake of chemoprevention as a strategy to reduce breast cancer risk. Programs to increase awareness and elucidate the barriers are critical for women to engage in cancer prevention and promote chemoprevention adherence.
format Online
Article
Text
id pubmed-3712728
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-37127282013-08-05 Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction Rahman, Rakhshanda Layeequr Pruthi, Sandhya Cancers (Basel) Review Women who are at high risk of breast cancer can be offered chemoprevention. Chemoprevention strategies have expanded over the past decade and include selective receptor modulator inhibitors and aromatase inhibitors. Physicians are expected to provide individualized risk assessments to identify high risk women who may be eligible for chemoprevention. It is prudent that physicians utilize a shared decision approach when counseling high risk women about their preventive options. Barriers and misperceptions however exist with patient and physician acceptance of chemoprevention and continue to impede uptake of chemoprevention as a strategy to reduce breast cancer risk. Programs to increase awareness and elucidate the barriers are critical for women to engage in cancer prevention and promote chemoprevention adherence. MDPI 2012-10-29 /pmc/articles/PMC3712728/ /pubmed/24213502 http://dx.doi.org/10.3390/cancers4041146 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Rahman, Rakhshanda Layeequr
Pruthi, Sandhya
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
title Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
title_full Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
title_fullStr Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
title_full_unstemmed Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
title_short Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
title_sort chemoprevention of breast cancer: the paradox of evidence versus advocacy inaction
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712728/
https://www.ncbi.nlm.nih.gov/pubmed/24213502
http://dx.doi.org/10.3390/cancers4041146
work_keys_str_mv AT rahmanrakhshandalayeequr chemopreventionofbreastcancertheparadoxofevidenceversusadvocacyinaction
AT pruthisandhya chemopreventionofbreastcancertheparadoxofevidenceversusadvocacyinaction